R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
A new era for the management of metastatic melanoma
TL;DR: The clinical development of ipilimumab and vemurafenib are reviewed and other promising immunological and molecular therapies being investigated for use in melanoma are discussed.
Journal ArticleDOI
Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.
Claire-Audrey Y. Bayan,Robyn D. Gartrell,Kimberly M. Komatsubara,Jaya Sarin Pradhan,Douglas K. Marks,Yan Lu,Margaret Borgardus,Syed Shabee Hasan,Adriana T. Lopez,Thomas D. Hart,Larisa J. Geskin,Bret Taback,Richard D. Carvajal,Gary K. Schwartz,Basil A. Horst,Yvonne M. Saenger +15 more
TL;DR: Predictive biomarkers for stratification of treatment with immunotherapy are urgently needed and quantitative multiplex immunofluorescence allows for staining of multiple markers for this purpose.
Journal ArticleDOI
A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies.
Prabhjot S. Mundi,Filemon S. Dela Cruz,Adina Grunn,Daniel Diolaiti,Audrey Mauguen,Allison R. Rainey,Kristina Guillan,Armaan Siddiquee,Daoqi You,Ronald Realubit,Charles Karan,Michael V. Ortiz,Eugene F. Douglass,Melissa K. Accordino,Suzanne Mistretta,Frances L. Brogan,Jeffrey N. Bruce,Cristina I. Caescu,Richard D. Carvajal,Katherine D. Crew,G. Joel DeCastro,Mark L. Heaney,Brian Henick,Dawn L. Hershman,Jun Hou,Fabio M. Iwamoto,Joseph G. Jurcic,Ravi P. Kiran,Michael D. Kluger,Teri N. Kreisl,E. Lamanna,Andrew B. Lassman,Emerson A. Lim,Gulam Abbas Manji,Guy M. McKhann,James M. McKiernan,Alfred I. Neugut,Kenneth P. Olive,Todd L. Rosenblat,Gary K. Schwartz,Catherine A. Shu,Michael B. Sisti,Ana I. Tergas,Reena Vattakalam,Mary Welch,Sven Wenske,Jason D. Wright,Peter Canoll,Hanina Hibshoosh,Kevin Kalinsky,Mahalaxmi Aburi,Peter J. Sims,Mariano J. Alvarez,Andrew L. Kung,Andrea Califano +54 more
TL;DR: In this paper , two transcriptome-based precision cancer medicine methodologies were evaluated to predict tumor sensitivity to a comprehensive repertoire of clinically relevant oncology drugs, whose mechanism-of-action was experimentally assessed in cognate cell lines.
Journal ArticleDOI
Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome
TL;DR: In this article, the Phase II efficacy and tolerability of edotecarin (J-107088) in patients with irinotecan-naive metastatic colorectal cancer (MCRC) were evaluated.
Journal ArticleDOI
Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.
Kimberly M. Komatsubara,Alexander N. Shoushtari,Sapna Pradyuman Patel,Parisa Momtaz,Shahnaz Singh-Kandah,Amanda Carter,Suzanne Cain,Lauren Taiclet,Sarah DeNoble,Tiffany Negri,Danielle Lacey,Grazia Ambrosini,Shing Mirn Lee,Gary K. Schwartz,Richard D. Carvajal +14 more
TL;DR: Uveal melanoma is a rare subtype of melanoma with no effective therapy for advanced disease and characterized by mutations in GNAQ and GNA11 leading to constitutive activation in patients with advanced disease.